(Q38614582)

4 September 2017

title

CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer (English)

1 reference

4 September 2017

0 references

0 references

0 references

1 reference

M Sachdeva

1

1 reference

4 September 2017

N Sachdeva

2

1 reference

4 September 2017

M Pal

3

1 reference

4 September 2017

N Gupta

4

1 reference

4 September 2017

I A Khan

5

1 reference

4 September 2017

M Majumdar

6

1 reference

4 September 2017

A Tiwari

7

1 reference

4 September 2017

publication date

23 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

22

1 reference

4 September 2017

issue

11

1 reference

4 September 2017

page(s)

509-517

1 reference

4 September 2017

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

FHIT: from gene discovery to cancer treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Influence of tumor-associated E-cadherin mutations on tumorigenicity and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Aberrant epigenetic landscape in cancer: how cellular identity goes awry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

DNA interrogation by the CRISPR RNA-guided endonuclease Cas9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Protospacer adjacent motif (PAM)-distal sequences engage CRISPR Cas9 DNA target cleavage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

CRISPR: new horizons in phage resistance and strain identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

RNA-guided editing of bacterial genomes using CRISPR-Cas systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Memory of viral infections by CRISPR-Cas adaptive immune systems: acquisition of new information

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Type I-E CRISPR-cas systems discriminate target from non-target DNA through base pairing-independent PAM recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Correction of a genetic disease in mouse via use of CRISPR-Cas9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Targeted mutagenesis in the model plant Nicotiana benthamiana using Cas9 RNA-guided endonuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Targeted genome modification of crop plants using a CRISPR-Cas system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

CRISPR-Cas systems for editing, regulating and targeting genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

RNA-guided gene activation by CRISPR-Cas9-based transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Evaluation of sgRNA target sites for CRISPR-mediated repression of TP53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Highly parallel identification of essential genes in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Genome-scale CRISPR-Cas9 knockout screening in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

CRISPR-mediated direct mutation of cancer genes in the mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

CRISPR-Cas9 knockin mice for genome editing and cancer modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

A chemical genetics approach for the functional assessment of novel cancer genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Efficient inversions and duplications of mammalian regulatory DNA elements and gene clusters by CRISPR/Cas9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Caveolin-1 inhibits breast cancer growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.54

Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.

21 January 2018

1 reference

12 December 2020

Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer

1 reference

12 December 2020

Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer.

1 reference

12 December 2020

Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs

1 reference

12 December 2020

Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/CGT.2015.54

1 reference

4 September 2017

1 reference